Prison officials launch a probe into Martin Shkreli’s latest antics, allegedly running his biotech business with a contraband cell phone

Martin Shkreli has found himself in another mess, and this one comes with a possible tack-on to his prison sentence of up to one year in the federal pen, plus a fine.

In the wake of the Wall Street Journal’s expose on Shkreli’s latest shenanigans, the US Bureau of Prisons has begun an investigation into the article’s claim that the ‘Pharma Bro,’ an avid smartphone user before he was sentenced to 7 years for fraud, has found himself a contraband cell phone to run his biotech business behind the walls of his low security prison Fort Dix.

Both the phone and the hands-on management while behind bars are strictly forbidden by the rules.

The Bureau tells me:

Administratively, Bureau of Prisons (BOP) Program Statement 5270.09 “Inmate Discipline Program” found here also describes possession of a cell phone as a “greatest severity level” prohibited act (see Code 108 on page 44).  Disciplinary sanctions which the inmate can receive are also described in the policy (see page 45). Additionally, inmates who conduct a business commit a “moderate severity level” prohibited act (see Code 334 on page 51) the disciplinary sanctions for these acts are likewise prescribed (see page 52).

The allegations, they tell me, are being investigated. And the possible sanctions can involve a quick move to a new cell as well as a pushback on any parole date.

Translation: Shkreli is in it up to his neck again.

Longtime observers will recall that Shkreli enjoyed nothing more than thumbing his nose at lawmakers and the law alike after he came into the spotlight for a 5000%-plus drug price hike. The drug pricing issue was all legal, of course, but a federal jury had a problem with his habit of continually lying to the investors in his hedge funds.

Image by Spencer Platt, Getty Images

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->